The American journal of clinical nutrition

Nutritional guidelines to support GLP-1 treatment for obesity: advice from major health and nutrition organizations

Updated

Abstract

GLP-1s can lead to body weight reductions of 5% to 18% in trials.

  • Real-world effectiveness of GLP-1s may be modestly lower than trial results.
  • Challenges associated with GLP-1 treatment include side effects like gastrointestinal issues and potential nutritional deficiencies.
  • Long-term adherence to GLP-1 treatment is often low, which may result in weight regain.
  • Multicomponent, evidence-based nutritional and behavioral therapies are recommended but not widely used alongside GLP-1s.
  • Key priorities for improving GLP-1 treatment include patient-centered initiation, comprehensive assessments, and ongoing nutritional management.

Simplified

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

Conflict of interest Dr. Mozaffarian reports research funding from the National Institutes of Health, Kaiser Permanente Fund at the East Bay Community Foundation, National Association of Chain Drug Stores Foundation, GoogleHealth, and The Rockefeller Foundation; scientific Advisory board, Beren Therapeutics, Brightseed, Calibrate, Elysium Health, Filtricine, HumanCo, Instacart Health, January Inc., WndrHLTH; scientific consulting, Amazon Health; equity in Calibrate and HumanCo; and chapter royalties from UpToDate. Dr. Apovian reports research funding from PCORI and GI Dynamics, Inc.; and Advisory boards for Altimmune, Inc., Arrowhead Pharmaceuticals, Inc., BioAge, Biolinq Incorporated, Caribou Biosciences, Inc., CinFina Pharma, Inc., Covidien LP, Cowen and Company, LLC, Currax Pharmaceuticals, LLC, EPG Communication Holdings Ltd., Form Health, Inc., Fractyl Health, Inc., LillyUSA, LLC, L-Nutra, Inc., Mediflix Inc., NeuroBo Pharmaceuticals, Inc., Neurocrine Biosciences, Inc., NodThera Limited, Nutrisystem, OptumRx, Inc., Pain Script Corporation, Palatin Technologies, Inc., Pursuit By You, Redesign Health Inc., ReShape Lifesciences Inc., Riverview School, Roman Health Ventures Inc., Scholar Rock, Inc., Terns, Inc., Verily Life SciencesLLC, Veru Inc., Vida Health, Inc., Wave Life Sciences, Xeno Biosciences and Zyversa Therapeutics, Inc. Dr. Butsch reports Advisory boards for Eli Lilly, Novo Nordisk, Abbott and Boehringer Ingelheim. S. Christensen reports Advisory boards and speakers bureau for Novo Nordisk and speakers bureau for Eli Lilly. Dr. Kane reports research funding by the Ardmore Institute of Health. Dr. Stanford reports research funding from the National Institutes of Health; and scientific Advisory boards for Eli Lilly, Novo Nordisk, Amgen, Pfizer, Currax, Calibrate, Vida Health, Ilant Health, Mellicell, Sweetch, Doximity, GoodRx, Empros Pharma, Clearmind Medicine, and Apnimed. The other authors report no disclosures. Dr. Alexander reports advisory board for Novo Nordisk and Speaker's Bureau for Eli Lilly.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free